Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in New-Onset Type 1 Diabetes Mellitus
NCT06227221Phase 2Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Feb 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of sorafenib in type 1 diabetes mellitus (T1D), sponsored by The Second Xiangya Hospital. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
sorafenib
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06227221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06227221.